We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Low-dose acyclovir prophylaxis for the prevention of herpes simplex virus disease after allogeneic hematopoietic stem cell transplantation.
- Authors
Kawamura, K; Wada, H; Yamasaki, R; Ishihara, Y; Sakamoto, K; Ashizawa, M; Sato, M; Machishima, T; Terasako, K; Kimura, S I; Kikuchi, M; Nakasone, H; Yamazaki, R; Kanda, J; Kako, S; Tanihara, A; Nishida, J; Kanda, Y
- Abstract
Currently, acyclovir (ACV) at 1000 mg/day is widely used as prophylaxis in the early phase of hematopoietic stem cell transplant (HSCT) in Japan. However, low-dose ACV (200 mg/day) has been shown to prevent varicella zoster virus reactivation in the middle and late phases of HSCT.
- Publication
Transplant infectious disease : an official journal of the Transplantation Society, 2013, Vol 15, Issue 5, p457
- ISSN
1399-3062
- Publication type
Journal Article
- DOI
10.1111/tid.12118